Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Esther H.L. Chan"'
Autor:
Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian Flinn, Werner Rabitsch, Yok-Lam Kwong, Marie J. Kersten, Monique C. Minnema, Harald Holte, Esther H.L. Chan, Joaquin Martinez-Lopez, Antonia M.S. Müller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David Bond, Charalambos Andreadis, Peter McSweeney, Mohamed Kharfan-Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin
Publikováno v:
New England Journal of Medicine, 386(7), 629-639. Massachussetts Medical Society
New England journal of medicine, 386(7), 629-639. Massachussetts Medical Society
Bishop, M R, Dickinson, M, Purtill, D, Barba, P, Santoro, A, Hamad, N, Kato, K, Sureda, A, Greil, R, Thieblemont, C, Morschhauser, F, Janz, M, Flinn, I, Rabitsch, W, Kwong, Y-L, Kersten, M J, Minnema, M C, Holte, H, Chan, E H L, Martinez-Lopez, J, Müller, A M S, Maziarz, R T, McGuirk, J P, Bachy, E, Gouill, S L, Dreyling, M, Harigae, H, Bond, D, Andreadis, C, McSweeney, P, Kharfan-Dabaja, M, Newsome, S, Degtyarev, E, Awasthi, R, del Corral, C, Andreola, G, Masood, A, Schuster, S J, Jäger, U, Borchmann, P & Westin, J R 2022, ' Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma ', New England Journal of Medicine, vol. 386, no. 7, pp. 629-639 . https://doi.org/10.1056/NEJMoa2116596
New England journal of medicine, 386(7), 629-639. Massachussetts Medical Society
Bishop, M R, Dickinson, M, Purtill, D, Barba, P, Santoro, A, Hamad, N, Kato, K, Sureda, A, Greil, R, Thieblemont, C, Morschhauser, F, Janz, M, Flinn, I, Rabitsch, W, Kwong, Y-L, Kersten, M J, Minnema, M C, Holte, H, Chan, E H L, Martinez-Lopez, J, Müller, A M S, Maziarz, R T, McGuirk, J P, Bachy, E, Gouill, S L, Dreyling, M, Harigae, H, Bond, D, Andreadis, C, McSweeney, P, Kharfan-Dabaja, M, Newsome, S, Degtyarev, E, Awasthi, R, del Corral, C, Andreola, G, Masood, A, Schuster, S J, Jäger, U, Borchmann, P & Westin, J R 2022, ' Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma ', New England Journal of Medicine, vol. 386, no. 7, pp. 629-639 . https://doi.org/10.1056/NEJMoa2116596
BACKGROUND: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for dif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d15c5a71064f7018247c023fe0a84bb
https://research.vumc.nl/en/publications/05692014-3989-41b0-9670-0dae99bc18df
https://research.vumc.nl/en/publications/05692014-3989-41b0-9670-0dae99bc18df